Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
Chair: Peter Schmid, UK; Presenter: Barbara Pistilli, France; Discussant: Veronique Dieras, France; AACR Expert Commentary: Sarat Chandarlapaty, USA